[go: up one dir, main page]

CL2022002606A1 - Implante ocular que contiene un inhibidor de la tirosina cinasa - Google Patents

Implante ocular que contiene un inhibidor de la tirosina cinasa

Info

Publication number
CL2022002606A1
CL2022002606A1 CL2022002606A CL2022002606A CL2022002606A1 CL 2022002606 A1 CL2022002606 A1 CL 2022002606A1 CL 2022002606 A CL2022002606 A CL 2022002606A CL 2022002606 A CL2022002606 A CL 2022002606A CL 2022002606 A1 CL2022002606 A1 CL 2022002606A1
Authority
CL
Chile
Prior art keywords
tyrosine kinase
kinase inhibitor
ocular implant
implant containing
hydrogel
Prior art date
Application number
CL2022002606A
Other languages
English (en)
Inventor
D Blizzard Charles
Driscoll Arthur
El-Hayek Rami
Goldstein Michael
Iacona Joseph
Jarrett Peter
S Jarrett Timothy
Kahn Erica
Lattrell Zachary
Original Assignee
Ocular Therapeutix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/029827 external-priority patent/WO2020219890A1/en
Application filed by Ocular Therapeutix Inc filed Critical Ocular Therapeutix Inc
Publication of CL2022002606A1 publication Critical patent/CL2022002606A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La invención se refiere a un implante ocular biodegradable de liberación sostenida que contiene un inhibidor de la tirosina cinasa disperso en un hidrogel para el tratamiento de una enfermedad de la retina durante un período de tiempo prolongado.
CL2022002606A 2020-03-25 2022-09-23 Implante ocular que contiene un inhibidor de la tirosina cinasa CL2022002606A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062994391P 2020-03-25 2020-03-25
PCT/US2020/029827 WO2020219890A1 (en) 2019-04-25 2020-04-24 Ocular hydrogel tyrosine kinase inhibitor implants
US202063106276P 2020-10-27 2020-10-27
US202163148463P 2021-02-11 2021-02-11

Publications (1)

Publication Number Publication Date
CL2022002606A1 true CL2022002606A1 (es) 2023-03-24

Family

ID=77411313

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002606A CL2022002606A1 (es) 2020-03-25 2022-09-23 Implante ocular que contiene un inhibidor de la tirosina cinasa

Country Status (20)

Country Link
US (4) US11439592B2 (es)
EP (2) EP4252725A3 (es)
JP (2) JP7378638B2 (es)
KR (2) KR20240142585A (es)
CN (1) CN115461040B (es)
AU (2) AU2021244485B2 (es)
BR (1) BR112022018815A2 (es)
CA (2) CA3234679A1 (es)
CL (1) CL2022002606A1 (es)
DK (1) DK3884929T3 (es)
ES (1) ES2952677T3 (es)
FI (1) FI3884929T3 (es)
HR (1) HRP20230800T1 (es)
HU (1) HUE062928T2 (es)
IL (1) IL296687A (es)
MX (2) MX2022010333A (es)
PL (1) PL3884929T3 (es)
PT (1) PT3884929T (es)
TW (1) TW202202138A (es)
WO (1) WO2021195163A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020022610A2 (pt) 2018-05-10 2021-02-09 Regeneron Pharmaceuticals, Inc. proteína de fusão de receptor de vegf de alta concentração que contém formulações
WO2020219890A1 (en) * 2019-04-25 2020-10-29 Ocular Therapeutix, Inc. Ocular hydrogel tyrosine kinase inhibitor implants
WO2021195163A1 (en) * 2020-03-25 2021-09-30 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
US20230390189A1 (en) * 2020-10-27 2023-12-07 Ocular Therapeutix, Inc. Ocular implant containing an active ingredient
EP4312917A1 (en) 2021-03-24 2024-02-07 Ocular Therapeutix, Inc. Implant injector device
CN118804742A (zh) * 2022-01-09 2024-10-18 视尔普斯眼科公司 包含抗微生物剂的小管内插入物
US20250064760A1 (en) * 2022-01-09 2025-02-27 Ocular Therapeutix, Inc. Intracanalicular insert comprising a non-steroidal anti-inflammatory agent
EP4469029A1 (en) * 2022-01-24 2024-12-04 Celanese EVA Performance Polymers LLC Implantable device for delivery of a tyrosine kinase inhibitor
KR20240115650A (ko) * 2023-01-19 2024-07-26 주식회사 스카이테라퓨틱스 티로신 키나아제 억제제의 무정형 나노 분자회합체와 이를 포함하는 조성물 및 그의 제조방법

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993071A (en) 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
US3949750A (en) 1974-10-07 1976-04-13 Freeman Jerre M Punctum plug and method for treating keratoconjunctivitis sicca (dry eye) and other ophthalmic aliments using same
US4915684A (en) 1988-06-21 1990-04-10 Mackeen Donald L Method and apparatus for modulating the flow of lacrimal fluid through a punctum and associated canaliculus
US5469867A (en) 1992-09-02 1995-11-28 Landec Corporation Cast-in place thermoplastic channel occluder
US6566406B1 (en) 1998-12-04 2003-05-20 Incept, Llc Biocompatible crosslinked polymers
US6027470A (en) 1998-06-10 2000-02-22 Eagle Vision, Inc. Punctum plug and method for inserting the same into the punctual opening
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6196993B1 (en) 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
US7347850B2 (en) 1998-08-14 2008-03-25 Incept Llc Adhesion barriers applicable by minimally invasive surgery and methods of use thereof
US6703047B2 (en) 2001-02-02 2004-03-09 Incept Llc Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
ATE324417T1 (de) 1999-12-17 2006-05-15 Biopolymer Products Of Sweden Polyphenolisches protein enthaltende bioadhäsive zusammensetzung
US20040175410A1 (en) 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US6982090B2 (en) 2001-05-10 2006-01-03 Gillespie Donald E More easily visualized punctum plug configurations
PL223153B1 (pl) 2002-09-18 2016-10-31 Allergan Inc Urządzenie do wszczepiania implantu okulistycznego
US20050283109A1 (en) 2003-03-07 2005-12-22 Peyman Gholam A Method and apparatus for lacrimal canal obstruction
US20050197614A1 (en) 2004-03-04 2005-09-08 Wilson Pritchard Occlusive biomedical devices, punctum plugs, and methods of use thereof
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
WO2005107708A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
US20080124400A1 (en) 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
ATE408432T1 (de) 2004-11-02 2008-10-15 Sydney Biotech Pty Ltd Extraokulare vorrichtung
EP1819696A1 (en) 2004-11-02 2007-08-22 Pfizer, Inc. Polymorphic forms of 6-2-(methylcarbamoyl)phenysulfanyl|-3-e-2-(pyridin-2-yl)ethenyl indazole
US11129690B2 (en) 2006-03-28 2021-09-28 Devicor Medical Products, Inc. Method for making hydrogel markers
US8939910B2 (en) 2006-03-28 2015-01-27 Devicor Medical Products, Inc. Method for enhancing ultrasound visibility of hyperechoic materials
ES2717607T3 (es) 2006-03-31 2019-06-24 Mati Therapeutics Inc Estructuras de administración de fármacos y composiciones para el sistema nasolagrimal
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US9173773B2 (en) 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
ES2565683T3 (es) 2006-09-15 2016-04-06 Xcovery, Inc. Compuestos inhibidores de quinasa
US20080114076A1 (en) 2006-11-09 2008-05-15 Alcon Manufacturing Ltd. Punctal plug comprising a water-insoluble polymeric matrix
US8080593B2 (en) 2006-11-29 2011-12-20 University Of Southern California Reversible thermoresponsive adhesives for implants
US8673286B2 (en) 2007-04-09 2014-03-18 Northwestern University DOPA-functionalized, branched, poly(aklylene oxide) adhesives
US20090227981A1 (en) 2007-03-05 2009-09-10 Bennett Steven L Low-Swelling Biocompatible Hydrogels
ES2634866T5 (es) 2007-04-05 2024-03-04 Pfizer Prod Inc Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-[2-(piridin-2-il)etenil]indazol adecuadas para el tratamiento del crecimiento celular anormal en mamíferos
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
WO2010093873A2 (en) 2009-02-12 2010-08-19 Incept, Llc Drug delivery through hydrogel plugs
US20100247606A1 (en) 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
SG177761A1 (en) 2009-07-31 2012-03-29 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
MX2012004499A (es) 2009-10-29 2012-05-29 Ascendis Pharma As Esterilizacion de hidrogeles biodegradables.
US9320647B2 (en) 2010-03-31 2016-04-26 Ocuject, Llc Device and method for intraocular drug delivery
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
US20130202587A1 (en) 2011-08-25 2013-08-08 Randox Laboratories Ltd. Identification of genetic variants
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
CA2858161C (en) 2011-12-05 2020-03-10 Incept, Llc Medical organogel processes and compositions
US20150037422A1 (en) * 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
US11779682B2 (en) 2012-04-30 2023-10-10 The Johns Hopkins University Electro-mechanically stretched micro fibers and methods of use thereof
US10119202B2 (en) 2012-04-30 2018-11-06 The Johns Hopkins University Method for preparing electro-mechanically stretched hydrogel micro fibers
WO2013177367A2 (en) 2012-05-23 2013-11-28 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
MX373894B (es) 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
HUE068493T2 (hu) 2013-03-08 2024-12-28 Polyactiva Pty Ltd Polimer konjugátum bioaktív szer szállításához
US10113033B2 (en) 2013-03-08 2018-10-30 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
EP2981248B1 (en) 2013-04-01 2020-09-02 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
EP3861982A3 (en) 2013-12-06 2021-09-01 Allergan, Inc. Intracameral implant for treatment of an ocular condition
KR20160126983A (ko) 2014-01-16 2016-11-02 온토제네시스, 엘엘씨 안내 혈관신생 및/또는 누출 치료용 조성물 및 방법
SI3102605T1 (sl) 2014-02-04 2019-04-30 Pfizer Inc. Kombinacija PD-1 antagonista in VEGFR inhibitorja za zdravljenje raka
KR20150115533A (ko) * 2014-04-04 2015-10-14 씨제이제일제당 (주) 1,5-디아미노펜탄의 정제방법
AU2015360469B2 (en) 2014-12-10 2021-03-25 Incept, Llc Hydrogel drug delivery implants
WO2016178150A1 (en) 2015-05-05 2016-11-10 Shilpa Medicare Limited Novel polymorphs of axitinib
US11369591B2 (en) 2015-05-12 2022-06-28 Incept, Llc Drug delivery from hydrogels
KR20240043821A (ko) 2015-06-06 2024-04-03 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
UA126892C2 (uk) 2015-06-16 2023-02-22 Мерк Патент Гмбх Спосіб лікування запущеної поширеної нирковоклітинної карциноми (arcc)
CN107949354B (zh) 2015-07-22 2022-02-18 因赛普特有限责任公司 涂覆的泪点塞
WO2017015616A1 (en) 2015-07-22 2017-01-26 Envisia Therapeutics, Inc. Ocular protein delivery
CN108601725B (zh) 2015-11-25 2024-03-08 因赛普特有限责任公司 形状改变的药物递送装置和方法
CN119656170A (zh) 2016-06-02 2025-03-21 拨康视云生物医药科技(广州)有限公司 使用尼达尼布来治疗具有异常新生血管形成的眼病的组合物和方法
JP7430529B2 (ja) * 2016-09-23 2024-02-13 インセプト・リミテッド・ライアビリティ・カンパニー 前房内薬物送達デポ
TWI647224B (zh) 2016-09-29 2019-01-11 大陸商貝達藥業股份有限公司 激酶抑制劑化合物的多晶型、含其的藥物組合物及其製備方法和應用
CA3039051A1 (en) 2016-10-05 2018-04-12 Titan Pharmaceuticals, Inc. Implantable devices for drug delivery with reduced burst release
EP3573641A4 (en) * 2017-01-25 2020-11-11 Iconic Therapeutics, Inc. TREATMENT METHODS FOR DISORDERS ASSOCIATED WITH ANGIOGENESIS AND NEOVASCULARIZATION
EP4537830A2 (en) 2017-06-13 2025-04-16 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices
CN111867631A (zh) 2018-03-16 2020-10-30 诺华股份有限公司 治疗眼部疾病的方法
CN118286445A (zh) 2019-03-05 2024-07-05 爱瑞制药公司 用于治疗眼部疾病或病症的药物组合物
WO2020219890A1 (en) 2019-04-25 2020-10-29 Ocular Therapeutix, Inc. Ocular hydrogel tyrosine kinase inhibitor implants
WO2020243608A1 (en) 2019-05-31 2020-12-03 Dose Medical Corporation Bioerodible polyester polymer implants and related methods of use
WO2021195163A1 (en) 2020-03-25 2021-09-30 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
US20220080044A1 (en) 2020-09-14 2022-03-17 National Yang-Ming University Method for preventing or treating peripheral arterial occlusive disease
US20230390189A1 (en) * 2020-10-27 2023-12-07 Ocular Therapeutix, Inc. Ocular implant containing an active ingredient

Also Published As

Publication number Publication date
TW202202138A (zh) 2022-01-16
CN115461040B (zh) 2025-04-01
AU2024203448A1 (en) 2024-06-13
BR112022018815A2 (pt) 2022-11-29
PL3884929T3 (pl) 2023-10-09
JP2023518820A (ja) 2023-05-08
US20220079876A1 (en) 2022-03-17
PT3884929T (pt) 2023-08-09
EP3884929B1 (en) 2023-06-14
US20220347094A1 (en) 2022-11-03
KR102707942B1 (ko) 2024-09-23
KR20240142585A (ko) 2024-09-30
EP4252725A2 (en) 2023-10-04
FI3884929T3 (fi) 2023-08-07
MX2022010333A (es) 2022-12-08
WO2021195163A1 (en) 2021-09-30
CN115461040A (zh) 2022-12-09
HRP20230800T1 (hr) 2023-10-27
JP2024012435A (ja) 2024-01-30
ES2952677T3 (es) 2023-11-03
AU2021244485B2 (en) 2024-05-16
KR20220157462A (ko) 2022-11-29
US11534396B2 (en) 2022-12-27
DK3884929T3 (da) 2023-09-25
IL296687A (en) 2022-11-01
CA3234679A1 (en) 2021-09-30
EP3884929A1 (en) 2021-09-29
CA3171563A1 (en) 2021-09-30
US20210308043A1 (en) 2021-10-07
JP7378638B2 (ja) 2023-11-13
HUE062928T2 (hu) 2023-12-28
MX2024012181A (es) 2024-11-08
AU2021244485A1 (en) 2022-09-15
US20230118774A1 (en) 2023-04-20
US11439592B2 (en) 2022-09-13
EP4252725A3 (en) 2023-11-22

Similar Documents

Publication Publication Date Title
CL2022002606A1 (es) Implante ocular que contiene un inhibidor de la tirosina cinasa
CO6351718A2 (es) Suministro de liberacion sostenida de agentes activos para tratar glaucoma e hipertension ocular
MX2023004614A (es) Implante ocular que contiene un agente activo.
CY1120299T1 (el) Μειωση ενδοφθαλμιας πιεσης με ενδοθαλαμικα εμφυτευματα βιματοπροστης
PH12019500423A1 (en) Pharmaceutical composition
CR10041A (es) Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
CL2020001183A1 (es) Implantes de liberación sostenida para reducir la presión intraocular con duración prolongada del efecto.
EA201071413A1 (ru) Способ и композиция для лечения повышения внутриглазного давления и глаукомы
AR048645A1 (es) Tratamientos para el implante ocular de efecto terapeutico prolongado
ES2538551B1 (es) Composición Oftálmica para la corrección de la presbicia
Obalum et al. Lower limb amputations at a Nigerian private tertiary hospital
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
JP1747386S (ja) 流体交換具
BR112023006371A2 (pt) Composição oftalmológica tópica
EA202191684A1 (ru) Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии
DE502004010981D1 (de) Intraokulare linseneinrichtung zur verbesserung des sehvermögens bei netzhauterkrankungen
MX2022009435A (es) Composiciones y metodos para el tratamiento de enfermedades oculares.
DOP2021000098A (es) Asesor de procedimiento corneal topográfico inteligente
JP2017505805A (ja) 老眼矯正に使用される眼科用薬理組成物及びその投与
ZA202209352B (en) Ocular implant containing a tyrosine kinase inhibitor
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
MX381356B (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
AR119968A1 (es) Dispositivo de anclaje escleral para soporte de lente intraocular y métodos quirúrgicos de inserción del dispositivo
Razmju et al. Effects of Cross-Linking on Visual Acuity in Patients with Keratoconus